Evidence map›Paper›PMID 40434588›Full record

ReviewHeart failure reviews2025

Synchronized diaphragmatic stimulation for the treatment of HFrEF-a review.

L R Goldberg, M Mirro, G Becker, T Shaburishvili, M Fudim

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart failure reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

L R GoldbergUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. Lee.Goldberg@pennmedicine.upenn.edu.ORCID 0000-0002-7906-9638
M MirroIndiana University School of Medicine and Parkview Mirro Center for Innovation, Fort Wayne, IN, USA.
G BeckerUniversity of George and Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia.
T ShaburishviliIlia State University and Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia.
M FudimDuke Clinical Research Institute and Duke Cardiology, Durham, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gap between maximally tolerated medical therapy and consideration for permanent mechanical circulatory support and/or cardiac transplant or palliative treatment of moderate to severe heart failure represents an underserved patient population. New therapies are evolving which may not only improve quality of life for these patients but also improve hemodynamics and potentially reverse the progression of the disease. This review is focused on one such therapy, synchronized diaphragmatic stimulation. Current clinical results suggest that patients experience improved exercise tolerance, quality of life, and hemodynamic function over 6-12 months of therapy which can be safely implemented through a minimally invasive laparoscopic procedure, often as an outpatient. This technology has been granted breakthrough device designation and is being evaluated for a double-blinded, randomized controlled trial by the US FDA.

Indexed as

DiaphragmElectric Stimulation TherapyHeart FailureExercise ToleranceHemodynamicsHumansQuality of LifeTreatment OutcomeGDMTHeart failureHFrEFIntrathoracic pressureMinimally invasiveSynchronized diaphragmatic stimulation

Identifiers

PMID40434588
PMCPMC12296808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.